ZA201901862B - Modified factor h binding protein - Google Patents

Modified factor h binding protein

Info

Publication number
ZA201901862B
ZA201901862B ZA2019/01862A ZA201901862A ZA201901862B ZA 201901862 B ZA201901862 B ZA 201901862B ZA 2019/01862 A ZA2019/01862 A ZA 2019/01862A ZA 201901862 A ZA201901862 A ZA 201901862A ZA 201901862 B ZA201901862 B ZA 201901862B
Authority
ZA
South Africa
Prior art keywords
binding protein
modified factor
factor
modified
protein
Prior art date
Application number
ZA2019/01862A
Other languages
English (en)
Inventor
M Tang Christoph
Original Assignee
Univ Oxford Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oxford Innovation Ltd filed Critical Univ Oxford Innovation Ltd
Publication of ZA201901862B publication Critical patent/ZA201901862B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
ZA2019/01862A 2016-08-31 2019-03-26 Modified factor h binding protein ZA201901862B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1614687.0A GB201614687D0 (en) 2016-08-31 2016-08-31 fHbp scaffold
PCT/GB2017/052535 WO2018042178A1 (en) 2016-08-31 2017-08-31 Modified factor h binding protein

Publications (1)

Publication Number Publication Date
ZA201901862B true ZA201901862B (en) 2020-09-30

Family

ID=57119942

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2019/01862A ZA201901862B (en) 2016-08-31 2019-03-26 Modified factor h binding protein

Country Status (13)

Country Link
US (1) US12497432B2 (enExample)
EP (1) EP3506934A1 (enExample)
JP (1) JP7525093B2 (enExample)
KR (1) KR102643280B1 (enExample)
CN (1) CN109890412B (enExample)
AU (1) AU2017319218B2 (enExample)
BR (1) BR112019003957A2 (enExample)
CA (1) CA3035159A1 (enExample)
GB (2) GB201614687D0 (enExample)
IL (1) IL265078B2 (enExample)
MX (1) MX420767B (enExample)
WO (1) WO2018042178A1 (enExample)
ZA (1) ZA201901862B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
CN110903400A (zh) * 2019-11-08 2020-03-24 苏州微超生物科技有限公司 B群脑膜炎球菌fHBP多变体融合蛋白及其制备方法与应用
CN111533792B (zh) * 2020-07-07 2020-10-16 康希诺生物股份公司 一种定点突变的载体蛋白及其在制备疫苗中的用途
US20230365979A1 (en) * 2020-09-29 2023-11-16 Idemitsu Kosan Co.,Ltd. Peptide tag and tagged protein including same
IN202321021121A (enExample) * 2023-03-24 2024-04-19

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7351413B2 (en) * 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
EP2351579B1 (en) * 2002-10-11 2016-09-21 Novartis Vaccines and Diagnostics S.r.l. Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
CA2509484C (en) * 2002-12-10 2012-03-20 Lorantis Ltd. Stabilized immunogenic hbc chimer particles
DK1587537T3 (da) * 2003-01-30 2012-07-16 Novartis Ag Injicerbare vacciner mod multiple meningococ-serogrupper
ES2397923T3 (es) * 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB2414667A (en) * 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
DE602005025647D1 (de) * 2004-07-23 2011-02-10 Novartis Vaccines & Diagnostic Polypeptide für die oligomerisierung von antigenen
GB0419408D0 (en) * 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
CN101107007B (zh) * 2005-01-27 2011-08-17 奥克兰儿童医院及研究中心 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
GB0524066D0 (en) * 2005-11-25 2006-01-04 Chiron Srl 741 ii
EP1925318A1 (en) * 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
AU2009215364B2 (en) * 2008-02-21 2014-09-18 Glaxosmithkline Biologicals S.A. Meningococcal fHBP polypeptides
AU2009223613B2 (en) * 2008-03-10 2014-09-25 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
MX2010012999A (es) * 2008-05-30 2012-03-07 U S A As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso.
EP2294085A1 (en) * 2008-06-09 2011-03-16 Novartis AG Antibodies against neisserial factor h binding protein
WO2010028096A2 (en) * 2008-09-03 2010-03-11 Children's Hospital & Research Center At Oakland Peptides presenting an epitope of an a domain of factor h binding protein and methods of use
GB0819633D0 (en) * 2008-10-25 2008-12-03 Isis Innovation Composition
CN104548082A (zh) * 2009-03-24 2015-04-29 诺华股份有限公司 为脑膜炎球菌因子h结合蛋白添加佐剂
US9266942B2 (en) * 2009-04-30 2016-02-23 Children's Hospital & Research Center Oakland Chimeric factor H binding proteins (fHbp) and methods of use
WO2011024072A2 (en) * 2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
CA2779816A1 (en) * 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
EP2544714A1 (en) * 2010-03-10 2013-01-16 GlaxoSmithKline Biologicals S.A. Vaccine composition
TR201802933T4 (tr) * 2010-03-30 2018-03-21 Childrens Hospital & Res Center At Oakland Özellikleri değiştirilmiş faktör h bağlama proteinleri (fhbp) ve bunların kullanım yöntemi.
EP2556085A2 (en) * 2010-04-05 2013-02-13 Bar-Ilan University Protease-activatable pore-forming polypeptides
WO2011161653A1 (en) * 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
KR101584871B1 (ko) * 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
WO2013078223A1 (en) * 2011-11-23 2013-05-30 Children's Hospital & Research Center Oakland Anti-factor h binding protein antibodies and methods of use thereof
EP2797624A1 (en) * 2011-12-29 2014-11-05 Novartis AG Adjuvanted combinations of meningococcal factor h binding proteins
WO2013132040A2 (en) * 2012-03-08 2013-09-12 Novartis Ag In vitro potency assay for protein-based meningococcal vaccines
SA115360586B1 (ar) * 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2865745C (en) * 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
ES2847923T3 (es) * 2012-06-14 2021-08-04 Glaxosmithkline Biologicals Sa Vacunas contra el meningococo del serogrupo X
GB201215005D0 (en) * 2012-08-23 2012-10-10 Isis Innovation Stabilised meningitis vaccine
CA2903716C (en) * 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
US20160030544A1 (en) * 2013-03-14 2016-02-04 Isis Innovation Limited Immunogenic composition to neisseria
RU2662968C2 (ru) * 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
CN106661092B (zh) * 2014-02-28 2021-07-06 葛兰素史密丝克莱恩生物有限公司 修饰的脑膜炎球菌fHbp多肽
BR112017001417B1 (pt) * 2014-07-23 2023-11-07 Children's Hospital & Research Center At Oakland Variantes da proteína de ligação ao fator h (fhbp), composição imunogênica e uso de uma fhbp variante referência cruzada
EP3223847A1 (en) 2014-11-28 2017-10-04 Janssen Vaccines & Prevention B.V. Meningitis b vaccine
KR20190049940A (ko) * 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
SG11201906519RA (en) * 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof

Also Published As

Publication number Publication date
CN109890412A (zh) 2019-06-14
IL265078A (enExample) 2019-04-30
IL265078B1 (en) 2023-04-01
MX420767B (es) 2025-02-10
JP7525093B2 (ja) 2024-07-30
KR102643280B1 (ko) 2024-03-05
CN109890412B (zh) 2025-04-04
GB201614687D0 (en) 2016-10-12
JP2019526261A (ja) 2019-09-19
GB2568440B (en) 2022-08-17
IL265078B2 (en) 2023-08-01
AU2017319218A2 (en) 2019-05-02
BR112019003957A2 (pt) 2019-06-25
EP3506934A1 (en) 2019-07-10
GB2568440A (en) 2019-05-15
NZ751995A (en) 2024-03-22
WO2018042178A1 (en) 2018-03-08
GB201903866D0 (en) 2019-05-08
US20220112249A1 (en) 2022-04-14
CA3035159A1 (en) 2018-03-08
KR20190064577A (ko) 2019-06-10
AU2017319218A1 (en) 2019-04-18
US12497432B2 (en) 2025-12-16
MX2019002248A (es) 2019-09-18
AU2017319218B2 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
ES3065767T3 (en) Bispecific binding proteins and uses thereof
IL272064A (en) Binding proteins 1
ZA201804317B (en) Altered april binding antibodies
ZA201802440B (en) Cd3 binding polypeptides
SG10202107880XA (en) Mesothelin binding proteins
RS67851B1 (sr) Proteini koji vezuju anti-tl1a antigen i njihova primena
GB201612520D0 (en) Binding molecules
GB201502305D0 (en) Protein
GB201502306D0 (en) Protein
SG11202001420VA (en) Modular binding proteins
IL259519B (en) cd131 binding proteins and their uses
SG10202111844VA (en) Cxcr4 binding molecules
GB201608197D0 (en) Novel proteins
GB201515745D0 (en) Proteins
GB201511787D0 (en) Proteins
GB2558968B (en) G Proteins
GB2568440B (en) Modified factor H binding protein
IL256298A (en) Multi-specific binding proteins
GB201513033D0 (en) Proteins
GB201615588D0 (en) TSLP Binding Proteins
IL269477A (en) Polypeptides that bind to IL-1R-1
ZA201906821B (en) Anti-jagged1 antigen binding proteins
GB201721503D0 (en) Modified globin proteins
GB201704006D0 (en) Modified globin proteins
GB201614627D0 (en) Antigen binding proteins